Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452348
Status:
COMPLETED
Last Update Posted:
2016-12-09
First Post:
2007-03-26
Brief Title:
A 12-Month Study Comparing Fluticasone PropionateSalmeterol ADVAIR DISKUS Combination Product 25050mcg Twice Daily To Fluticasone Propionate FLOVENT DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A 52-week Randomized Double-Blind Parallel-Group Study of Fluticasone PropionateSalmeterol DISKUS Combination Product FSC 25050 mcg BID and Fluticasone Propionate FP DISKUS 250 mcg BID in Treatment of Subjects With Asthma
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist salmeterol to constant dose of an inhaled corticosteroid fluticasone propionate in symptomatic subjects with asthma The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy The safety measure will be an assessment of adverse events
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None